For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | - | - | 7,353 | 6,821 |
| Total revenues | 58,818 | 69,802 | 69,462 | 101,685 |
| Cost of product sales | 4,606 | 5,955 | 4,753 | 4,504 |
| Research and development | 11,676 | 10,685 | - | - |
| Selling, general and administrative | 30,651 | 29,992 | 28,936 | 29,257 |
| Total costs and expenses | 46,933 | 46,632 | 41,042 | 40,582 |
| Income from operations | 11,885 | 23,170 | 28,420 | 61,103 |
| Interest income | 1,205 | 1,243 | 1,094 | 753 |
| Interest expense | 1,433 | 1,699 | 1,894 | 1,874 |
| Income before income taxes | 11,657 | 22,714 | 27,620 | 59,982 |
| Provision for income taxes | 3,003 | -245,351 | -280 | 369 |
| Net income | 8,654 | 268,065 | 27,900 | 59,613 |
| Basic EPS | 0.47 | 14.715 | 1.55 | 3.33 |
| Diluted EPS | 0.44 | 13.489 | 1.46 | 3.28 |
| Basic Average Shares | 18,412,000 | 18,217,000 | 18,038,000 | 17,885,000 |
| Diluted Average Shares | 19,686,000 | 19,873,000 | 19,156,000 | 18,162,000 |
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)